Best Practice Case Studies-Case 142 Asset 3 Performance-Enhancing Drugs

Video Transcription

Video Summary

Dr. Gary Green gave an overview of performance-enhancing drugs, anti-doping science, and the challenges of keeping sports fair. He emphasized that doping is an old problem, with athletes using substances for centuries, and that anti-doping is a constant “cat and mouse” game as athletes and suppliers develop new ways to evade detection.<br /><br />He organized substances into three groups: ergogenic drugs to improve performance, recreational drugs, and therapeutic drugs used for legitimate medical reasons. He explained how World Anti-Doping Agency rules are built around performance enhancement, health risk, and the “spirit of sport,” and how therapeutic use exemptions allow some athletes to use needed medications under strict conditions.<br /><br />The lecture focused on major drug classes, especially anabolic steroids, human growth hormone, EPO, and newer agents like SARMs. Dr. Green reviewed both the performance benefits and serious harms, including cardiovascular risk, liver injury, tendon rupture, endocrine suppression, psychiatric effects, and in youth, premature closure of growth plates and suicidality. He also described how testing has evolved, including testosterone/epitestosterone ratios, carbon isotope testing, growth hormone isoform and biomarker testing, and blood-based methods for EPO and transfusion detection.<br /><br />He highlighted that testing alone is not enough; deterrence also depends on education, strict liability, sanctions, and limiting access to contaminated supplements. He noted that many positive tests originate from broader systems involving physicians, coaches, and support staff. The session closed with examples of successful anti-doping efforts in MLB and a reminder that fair competition remains an important ethical ideal.

Meta Tag

Edition 4th Edition

Related Case 4th Edition, Case 142

Topic Metabolic

Keywords

4th Edition

4th Edition, Case 142

Metabolic

performance-enhancing drugs

anti-doping

WADA rules

anabolic steroids

human growth hormone

EPO

SARMs

drug testing

therapeutic use exemptions

fair competition